Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 10.843
Filtrar
1.
BMC Med Educ ; 22(1): 812, 2022 Nov 26.
Artigo em Inglês | MEDLINE | ID: mdl-36435782

RESUMO

BACKGROUND: Concerns around staffs' and students' interactions with commercial entities, for example drug companies, have led several North American medical schools to implement conflict of interest (COI) policies. However, little is known about COI policies at European medical schools. We analysed the content and strength of COI policies at Scandinavian medical schools. METHODS: We searched the websites of medical schools in Denmark, Norway, and Sweden and emailed the Deans for additional information. Using comparable methodology to previous studies, the strength of the COI policies was rated on a scale from 0 to 2 across 11 items (higher score more restrictive); we also assessed the presence of oversight mechanisms and sanctions. RESULTS: We identified 77 unique policies for 15 medical schools (range 2-8 per school). Most of the policies (n = 72; 94%) were University wide and only five (6%) were specific for the medical schools. For six of eleven items one or more schools had a restrictive policy (score of two). None of the schools had a restrictive policy for the five additional items (speaking relationships, sales representatives, on-site education activities, medical school curriculum, and drug samples). Honoraria was the item with the highest score, with eight of the 15 schools having a score of two. Thirteen of the 15 schools had policies that identified a party responsible for policy oversight and mentioned sanctions for non-compliance. CONCLUSION: Our study provides the first evaluation of all Scandinavian medical schools' COI policies. We found that the content of COI policies varies widely and still has shortcomings. We encourage Scandinavian medical schools to develop more stringent COI policies to regulate industry interactions with both faculty and students.


Assuntos
Conflito de Interesses , Faculdades de Medicina , Humanos , Estudos Transversais , Políticas , Política Organizacional
2.
Ned Tijdschr Geneeskd ; 1662022 07 28.
Artigo em Holandês | MEDLINE | ID: mdl-36300482

RESUMO

The number of new oncological treatments is increasing rapidly, even though many offer limited benefit to patients. In these cases, the scientific research leading to approvals is marred by shortcomings. Nonetheless, many drugs of limited value are approved by regulatory agencies. One of the factors contributing thereto is financial conflict of interest (FCI) with the pharmaceutical industry (Pharma). This occurs at different levels, including researchers, opinion leaders and editors of medical journals. FCI contributes to patient exposure to treatments that offer limited or no benefit and to unjust spending of valuable resources while providing large revenues for Pharma. The important step of the 'NederlandsTijdschriftvoorGeneeskunde' (NTVG) to omit all pharmaceutical advertisement as well as advertisement for pharmaceutical industry sponsored medical education sends an important signal and is a first step to revalue the important relationship with the pharmaceutical industry.


Assuntos
Antineoplásicos , Conflito de Interesses , Humanos , Publicidade , Indústria Farmacêutica , Antineoplásicos/uso terapêutico , Preparações Farmacêuticas
3.
Ned Tijdschr Geneeskd ; 1662022 10 20.
Artigo em Holandês | MEDLINE | ID: mdl-36300497

RESUMO

Independence is crucial for the quality and credibility of scientific recommendations and guidelines. The composition of advisory committees requires a full understanding of the relationships and interests of prospective committee members. In addition to financial relationships, intellectual interests, professional interests, and reputation may also play a role. In addition to preventing conflicts of interest among committee members, precautions are also required during the review and authorisation stages of draft recommendations. We describe which potential or perceived conflicts of interests may occur, and how quality and independence of the advisory process can be safeguarded.


Assuntos
Comitês Consultivos , Conflito de Interesses , Humanos , Estudos Prospectivos
4.
Rev Panam Salud Publica ; 46, oct. 2022. Special Issue Tobacco Control
Artigo em Espanhol | PAHO-IRIS | ID: phr-56455

RESUMO

[RESUMEN]. El presente informe especial describe tanto la metodología para el cálculo del indicador sobre adopción de mecanismos eficaces para evitar la interferencia de la industria tabacalera o de aquellos que defienden sus intereses, establecido en la “Estrategia y plan de acción para fortalecer el control del tabaco en la Región de las Américas 2018-2022”, así como del estado de adopción de estos mecanismos en los países de la Región para el año 2019, y su progreso desde 2016. Se encontró que, para el 2019, de los 35 Estados Miembros de la Organización Panamericana de la Salud (OPS), 13 cuentan con normativa que establece medidas especí- ficas al manejo de conflicto de interés para funcionarios y empleados públicos con competencia en políticas de control del tabaco. Asimismo, 7 han implementado medidas relacionadas, pero no específicas, y 14 no han implementado ninguna medida. Si bien se muestra un avance en relación con año 2016, los esfuerzos deben ser redoblados para alcanzar la meta de 20 Estados Miembros con mecanismos de identificación y manejo de conflictos de interés, establecida en la Estrategia y plan de acción. Cabe destacar que contar con normativa referida al tema no agota, ni mucho menos, concluye el cumplimiento de todas las obligaciones que emanan del artículo 5.3 del Convenio Marco de la Organización Mundial de la Salud para el Control del Tabaco. La Secretaría de OPS, en cumplimiento de lo solicitado por los Estados Miembros, desarrolló la metodología para el cálculo del indicador y sistematizó los hallazgos que son presentados.


[ABSTRACT]. This special report describes the methodology for calculating the indicator for the adoption of effective mecha- nisms to counter interference by the tobacco industry and those who work to further its interests, as established in the Strategy and Plan of Action to Strengthen Tobacco Control in the Region of the Americas 2018-2022; the report also presents the status of adoption of these mechanisms in the countries of the Region as of 2019, and progress since 2016. It was found that, as of 2019, of the 35 Pan American Health Organization (PAHO) Member States 13 had regulations establishing specific measures for managing conflicts of interest for gover- nment officials and employees with responsibility for tobacco control policies; seven had implemented related but nonspecific measures; and 14 had not implemented any measure. Although there has been progress since 2016, efforts must be redoubled to reach the target of 20 Member States having mechanisms for the identifi- cation and management of conflicts of interest, as established in the Strategy and Plan of Action. It should be noted that having regulations on the subject does not fulfill, nor by any means fully meet, all the obligations arising from Article 5.3 of the World Health Organization Framework Convention on Tobacco Control. The PAHO Secretariat, in response to requests by Member States, developed the methodology for calculation of the indicator and systematized the findings that are presented.


[RESUMO]. Este relatório especial descreve tanto a metodologia de cálculo do indicador sobre a adoção de mecanis- mos eficazes para evitar a interferência da indústria do tabaco ou daqueles que defendem seus interesses, estabelecida na “Estratégia e plano de ação para fortalecer o controle do tabagismo na Região das Amé- ricas 2018-2022”, quanto a situação da adoção desses mecanismos nos países da Região para o ano de 2019, e seu progresso desde 2016. Constatou-se que, até 2019, dos 35 Estados Membros da Organização Pan-Americana da Saúde (OPAS), 13 possuíam regulamentações que estabelecem medidas específicas para o manejo de conflitos de interesse para funcionários públicos responsáveis por políticas de controle do tabaco. Da mesma forma, 7 haviam implementado medidas relacionadas, mas não específicas, e 14 não haviam implementado nenhuma medida. Embora haja avanços em relação a 2016, os esforços devem ser redobrados para atingir a meta estabelecida na estratégia e no plano de ação de 20 Estados Membros com mecanismos de identificação e gestão de conflitos de interesse. Vale destacar que ter regulamentação sobre o tema não esgota, muito menos conclui, o cumprimento de todas as obrigações que emanam do artigo 5.3 da Convenção-Quadro da Organização Mundial da Saúde para o Controle do Tabaco. A Secretaria da OPAS, em cumprimento ao que foi solicitado pelos Estados Membros, desenvolveu a metodologia para o cálculo do indicador e sistematizou os resultados aqui apresentados.


Assuntos
Indústria do Tabaco , Controle e Fiscalização de Produtos Derivados do Tabaco , Conflito de Interesses , Estratégias de Saúde , América , Indústria do Tabaco , Controle e Fiscalização de Produtos Derivados do Tabaco , Conflito de Interesses , Estratégias de Saúde , América , Indústria do Tabaco , Controle e Fiscalização de Produtos Derivados do Tabaco , Conflito de Interesses , Estratégias de Saúde , América
5.
Rev Panam Salud Publica ; 46, oct. 2022. Special Issue Tobacco Control
Artigo em Inglês | PAHO-IRIS | ID: phr-56070

RESUMO

[ABSTRACT]. Objective. To explore the association between reporting conflict of interest (COI) and having a positive outcome toward vaping in scientific articles. Methods. A cross-sectional study that analyzed a sample of 697 articles published between 2017 and 2020 regarding vaping. Information on the reporting of COI, type of COI (no conflict, conflict with the tobacco industry, pharmaceutical industry, or other), and country of publication were collected. To explore the association between reporting COI and having a positive result for vaping, two logistic regression models were fitted, both adjusted by country of publication. Results. From 88 articles that reported COI, 23 reported COI with the tobacco industry, 44 with the pharmaceutical industry, and 21 reported another type of conflict. We found that reporting any type of COI increased by 4.7 times the odds (OR 4.70; 95% CI [2.89, 7.65]) of having a positive result for vaping. Additionally, compared to other countries, manuscripts published in England had 2 times higher odds (OR 2.40; 95% CI [1.16, 4.98]) of reporting a positive result for vaping. Reporting COI with the tobacco and pharmaceutical industries increased the odds of favorable results by 29 times (OR 29.95; 95% CI [9.84, 90.98]) and 2 times (OR 2.87; 95% CI [1.45, 5.69]), respectively. Conclusions. In scientific articles, reporting COI and having positive results for vaping are highly associated. COI should be considered and caution should be exercised when using data for policy-making.


[RESUMEN]. Objetivo. Explorar la relación entre notificar la existencia de conflictos de intereses y tener un resultado positivo con respecto al vapeo en los artículos científicos. Métodos. Se realizó un estudio transversal que analizó una muestra de 697 artículos sobre vapeo publicados entre 2017 y 2020. Se recopiló información sobre la notificación de la existencia de conflictos de intereses, los tipos de conflicto (sin conflicto o conflicto con la industria tabacalera, con la industria farmacéutica o con otras industrias) y el país de publicación. Para explorar la relación entre notificar la existencia de conflictos de intereses y tener un resultado positivo respecto del vapeo, se adaptaron dos modelos de regresión logística, y ambos se ajustaron por país de publicación. Resultados. De los 88 artículos en los que se notificó la existencia de conflictos de intereses, 23 informaron sobre conflictos de intereses con la industria tabacalera, 44 sobre conflictos con la industria farmacéutica y 21 sobre otros tipos de conflicto. Se determinó que la notificación de cualquier tipo de conflicto de intereses incrementó en 4,7 veces las probabilidades (OR 4,70; IC del 95 % [2,89; 7,65]) de obtener un resultado positivo con respecto al vapeo. Además, en comparación con otros países, los artículos publicados en Inglaterra mostraron probabilidades 2 veces más altas (OR 2,40; IC del 95 % [1,16; 4,98]) de comunicar un resultado positivo respecto del vapeo. Informar sobre la existencia de conflictos de intereses con las industrias tabacalera y farmacéutica multiplicó las probabilidades de resultados favorables por 29 (OR 29,95; IC del 95 % [9,84; 90,98]) y por 2 (OR 2,87; IC del 95% [1,45; 5,69]), respectivamente. Conclusiones. En los artículos científicos, existe una clara relación entre notificar la existencia de conflictos de intereses y tener un resultado positivo con respecto al vapeo. Se debe considerar el conflicto de intereses y actuar con precaución al emplear estos datos para la formulación de políticas.


[RESUMO]. Objetivo. Examinar a associação entre declarar conflitos de interesses e obter resultados favoráveis sobre os cigarros eletrônicos em artigos científicos. Métodos. Estudo transversal que analisou uma amostra de 697 artigos sobre cigarros eletrônicos publicados entre 2017 e 2020. Foram coletadas informações sobre a declaração de conflito de interesses, tipo de conflito (ausência de conflito, conflito com a indústria tabagista ou farmacêutica, ou outras formas de conflito) e o país de publicação do estudo. Dois modelos de regressão logística foram criados, com ajuste por país de publicação, para examinar a associação entre declarar conflitos de interesses e obter resultados favoráveis para os cigarros eletrônicos. Resultados. De 88 artigos que continham a declaração de conflitos de interesses, 23 informaram conflitos com a indústria tabagista, 44 com a indústria farmacêutica e 21 outras formas de conflito. Declarar qualquer tipo de conflito de interesses foi associado a uma probabilidade 4,7 vezes maior (OR 4,70; IC 95% [2,89, 7,65]) de obter resultados favoráveis aos cigarros eletrônicos. Quanto aos países de publicação, verificou-se uma probabilidade duas vezes maior de os artigos publicados na Inglaterra (OR 2,40; IC 95% [1,16, 4,98]) informarem resultados favoráveis para os cigarros eletrônicos. Quando se declarou o conflito de interesses com as indústrias tabagista e farmacêutica, a chance de resultados favoráveis nos estudos foi 29 vezes maior (OR 29,95; IC 95% [9,84, 90,98]) e 2 vezes maior (OR 2,87; IC 95% [1,45, 5,69]), respectivamente. Conclusões. Observa-se uma forte associação entre declarar o conflito de interesses e obter resultados favoráveis para os cigarros eletrônicos em artigos científicos. O conflito de interesses deve ser levado em consideração, recomendando-se cautela ao utilizar os dados de estudos na formulação de políticas.


Assuntos
Conflito de Interesses , Saúde Pública , Sistemas Eletrônicos de Liberação de Nicotina , Indústria do Tabaco , Formulação de Políticas , Conflito de Interesses , Saúde Pública , Sistemas Eletrônicos de Liberação de Nicotina , Indústria do Tabaco , Formulação de Políticas , Conflito de Interesses , Saúde Pública , Sistemas Eletrônicos de Liberação de Nicotina , Indústria do Tabaco , Formulação de Políticas
6.
Obstet Gynecol ; 140(5): 904-911, 2022 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-36265173

RESUMO

Developers and manufacturers of pharmaceutical agents and medical devices assist physicians in the pursuit of their educational goals and objectives through financial support of various medical, research, and educational programs. In general, industry seeks to optimize profit by providing useful goods and services. However, industry priorities may not always align with the ethical responsibilities of clinicians to promote the best interests of their patients, of educators to provide evidence-based instruction, and of researchers to ensure the scientific integrity of their investigations. To minimize both actual and perceived conflicts of interest, physicians and institutions should set guidelines for themselves and their employees regarding acceptable interaction with industry representatives. In this Committee Statement, the American College of Obstetricians and Gynecologists' Committee on Ethics provides recommendations for the management of professional relationships with industry, with an updated literature review and discussion of prevalence, regulations, and the effects of industry involvement in clinical care, education, and research.


Assuntos
Pesquisa Biomédica , Médicos , Humanos , Conflito de Interesses , Indústria Farmacêutica , Apoio Financeiro , Preparações Farmacêuticas
7.
Health Policy ; 126(12): 1233-1240, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36202647

RESUMO

Following a series of major scandals over the past two decades, the medical device industry is now undergoing a major regulatory change: the implementation of the European Union Medical Device Regulation (MDR) of 2017. After a transitional period of four years, the MDR became fully binding in May 2021. Although the medium- and long-term impacts of the MDR are still unclear, a range of scholars, health care professionals, and industry representatives have begun to publish early evidence and publicize their views on how the new regulation may impact free trade and patient safety. Even a cursory view of their output reveals hypotheses and opinions that could hardly be more divergent. The reasons for this disagreement are unclear and may extend beyond the different interests of the various stakeholder groups. To find out why this might be the case, we examine the MDR and seek to improve scholarly understanding of this most extensive regulation of medical devices since the early 1990s. We offer policymakers suggestions to help them improve future regulation. Based on theoretical considerations, we conclude that while the MDR is highly likely to strengthen the internal market of the EU, its impact on patient safety will remain unclear as long as there are no comprehensive studies on this topic that are based on empirical data.


Assuntos
Objetivos , Legislação de Dispositivos Médicos , Humanos , União Europeia , Conflito de Interesses , Segurança do Paciente
8.
Ned Tijdschr Geneeskd ; 1662022 Oct 20.
Artigo em Holandês | MEDLINE | ID: mdl-36300453

RESUMO

Guidelines are undeniably of great value to practicing physicians, but there are also objections. Due to the multitude of guidelines, it is sometimes difficult to find the most appropriate and it is not always clear how well-founded recommendations are. In addition, guidelines can limit the freedom of action. Also, in individual patients - especially in the case of multimorbidity - recommendations from different guidelines can conflict with each other. Finally, drawing up guidelines takes a lot of time, which is at the expense of patient care, and conflicts of interest are difficult to avoid completely. It is therefore important to put the recommendations from guidelines into perspective: they are an aid to individual patient care, not a law. This perspective is also important in education, so that students are taught to use guidelines in a wise way. Finally, it is important to regularly evaluate recommendations and revise them if necessary.


Assuntos
Conflito de Interesses , Médicos , Humanos , Bengala , Multimorbidade
10.
PLoS One ; 17(10): e0275380, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36206207

RESUMO

Mathematical models have become very influential, especially during the COVID-19 pandemic. Data and code sharing are indispensable for reproducing them, protocol registration may be useful sometimes, and declarations of conflicts of interest (COIs) and of funding are quintessential for transparency. Here, we evaluated these features in publications of infectious disease-related models and assessed whether there were differences before and during the COVID-19 pandemic and for COVID-19 models versus models for other diseases. We analysed all PubMed Central open access publications of infectious disease models published in 2019 and 2021 using previously validated text mining algorithms of transparency indicators. We evaluated 1338 articles: 216 from 2019 and 1122 from 2021 (of which 818 were on COVID-19); almost a six-fold increase in publications within the field. 511 (39.2%) were compartmental models, 337 (25.2%) were time series, 279 (20.9%) were spatiotemporal, 186 (13.9%) were agent-based and 25 (1.9%) contained multiple model types. 288 (21.5%) articles shared code, 332 (24.8%) shared data, 6 (0.4%) were registered, and 1197 (89.5%) and 1109 (82.9%) contained COI and funding statements, respectively. There was no major changes in transparency indicators between 2019 and 2021. COVID-19 articles were less likely to have funding statements and more likely to share code. Further validation was performed by manual assessment of 10% of the articles identified by text mining as fulfilling transparency indicators and of 10% of the articles lacking them. Correcting estimates for validation performance, 26.0% of papers shared code and 41.1% shared data. On manual assessment, 5/6 articles identified as registered had indeed been registered. Of articles containing COI and funding statements, 95.8% disclosed no conflict and 11.7% reported no funding. Transparency in infectious disease modelling is relatively low, especially for data and code sharing. This is concerning, considering the nature of this research and the heightened influence it has acquired.


Assuntos
COVID-19 , Doenças Transmissíveis , COVID-19/epidemiologia , Doenças Transmissíveis/epidemiologia , Conflito de Interesses , Revelação , Humanos , Pandemias
11.
Alcohol Clin Exp Res ; 46(10): 1771, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-36261850
12.
Surgery ; 172(5): 1429-1433, 2022 11.
Artigo em Inglês | MEDLINE | ID: mdl-36096965

RESUMO

BACKGROUND: The use of robotics in hepatobiliary and pancreatic surgery has increased. With this increased collaboration, there has also been a push toward improving the transparency of conflicts of interest in terms of funding provided by robotics companies. METHODS: Studies with ≥1 American author published between 2016 and 2020 discussing robotic hepatobiliary and pancreatic surgery were included in the analysis. The Centers for Medicare and Medicaid Services Open Payments Program was used to evaluate the accuracy of industry payment disclosures. Conflict of interest was defined as a lack of disclosure of ≥$100 funding from any robotics company in the United States. The primary outcome of this study was to determine the efficacy of the current standard conflict of interest reporting in surgery. RESULTS: A total of 355 studies (2,413 authors) were included. Of the studies that received robotics funding (n = 133), 20.3% did not disclose their conflicts of interest, whereas 79.7% had a conflict of interest disclosure. However, most of the disclosures (76.5%) were inaccurate. CONCLUSION: The findings of this study require an update in journal policies to ensure the accurate disclosure of conflicts of interest in robotic hepatobiliary and pancreatic surgery studies. Similarly, the investigators should ensure that their disclosures are accurate. Finally, surgeons must be more on top of their relationships with these companies and consider their vulnerability to bias.


Assuntos
Conflito de Interesses , Revelação , Idoso , Centers for Medicare and Medicaid Services, U.S. , Humanos , Indústrias , Medicare , Estados Unidos
13.
BMJ Open ; 12(9): e063501, 2022 09 19.
Artigo em Inglês | MEDLINE | ID: mdl-36123074

RESUMO

OBJECTIVES: The purpose of this study was to conduct a methodological review of research on the effects of conflicts of interest (COIs) in research contexts. DESIGN: Methodological review. DATA SOURCES: Ovid. ELIGIBILITY CRITERIA: Studies published between 1986 and 2021 conducting quantitative assessments of relationships between industry funding or COI and four target outcomes: positive study results, methodological biases, reporting quality and results-conclusions concordance. DATA EXTRACTION AND SYNTHESIS: We assessed key facets of study design: our primary analysis identified whether studies stratified industry funding or COI variables by magnitude (ie, number of COI or disbursement amount), type (employment, travel fees, speaking fees) or if they assessed dichotomous variables (ie, conflict present or absent). Secondary analyses focused on target outcomes and available effects measures. RESULTS: Of the 167 articles included in this study, a substantial majority (98.2%) evaluated the effects of industry sponsorship. None evaluated associations between funding magnitude and outcomes of interest. Seven studies (4.3%) stratified industry funding based on the mechanism of disbursement or funder relationship to product (manufacturer or competitor). A fifth of the articles (19.8%) assessed the effects of author COI on target outcomes. None evaluated COI magnitude, and three studies (9.1%) stratified COI by disbursement type and/or reporting practices. Participation of an industry-employed author showed the most consistent effect on favourability of results across studies. CONCLUSIONS: Substantial evidence demonstrates that industry funding and COI can bias biomedical research. Evidence-based policies are essential for mitigating the risks associated with COI. Although most policies stratify guidelines for managing COI, differentiating COIs based on the type of relationship or monetary value, this review shows that the available research has generally not been designed to assess the differential risks of COI types or magnitudes. Targeted research is necessary to establish an evidence base that can effectively inform policy to manage COI.


Assuntos
Pesquisa Biomédica , Conflito de Interesses , Revelação , Humanos , Indústrias , Políticas
14.
Rev. clín. esp. (Ed. impr.) ; 222(7): 393-400, ago. - sept. 2022. tab
Artigo em Espanhol | IBECS | ID: ibc-207421

RESUMO

Introducción En julio del 2020 se presentó en el Congreso de los Diputados español una propuesta de ley que proponía que la formación médica continuada se financiase exclusivamente por las Administraciones públicas, prohibiendo la participación privada. Objetivos Recoger la opinión de médicos y farmacéuticos sobre la propuesta de ley, conocer qué piensan acerca de la financiación de la formación médica continuada y su posible conflicto de interés. Métodos Estudio descriptivo transversal a través de una encuesta de opinión, voluntaria y anonimizada, dirigida a médicos y farmacéuticos hospitalarios. Resultados Se analizan 435 encuestas, el 59,8% de mujeres. El 87,6% son facultativos especialistas y el 77,2% pertenece a especialidades médicas. El 55,2% no está de acuerdo con la propuesta de ley. El 92,4% se muestra de acuerdo con que el Estado y las instituciones privadas subvencionen la formación de sus trabajadores. El 54,2% está en desacuerdo con que cada profesional financie su formación, mientras que el 14% está de acuerdo. El 19,8% no se ha sentido cómodo cuando le han financiado un curso o congreso y el 74,5% considera que la participación privada de la financiación no influye en la prescripción. Conclusiones La mayoría de los encuestados no está de acuerdo con una propuesta de ley que pretende prohibir que la industria farmacéutica financie la formación médica continuada. Casi todos se muestran de acuerdo con que el Estado y las instituciones privadas subvencionen la formación de sus trabajadores. En general, los encuestados no detectan conflictos de interés en su relación con la industria (AU)


Introduction In July 2020, a draft bill was introduced in Spain's Congress which proposed that continuing medical education be funded exclusively by the Spanish government, barring involvement from private entities. Aims This work aims to gather physicians’ and pharmacists’ opinions on this draft bill, learn what they think about the funding of continuing medical education and possible conflicts of interest. Methods This work is a descriptive cross-sectional study conducted via voluntary anonymous surveys aimed at physicians and hospital pharmacists. Results Four hundred thirty-five surveys were analyzed, 59.8% of which were from women. Of the respondents, 87.6% were specialist physicians and 77.2% were part of a specialist department. A total of 55.2% did not agree with the draft bill while 92.4% agreed that the government and private institutes should subsidize training for their workers. Furthermore, 52.4% disagreed that each professional should pay for his or her own training while 14% agreed they should. A total of 19.8% have felt uncomfortable when a course or conference has been paid for by another entity and 74.5% believe that the involvement of private entities in funding does not influence prescribing. Conclusions The majority of those surveyed did not agree with a draft bill aimed at prohibiting the pharmaceutical industry from funding continuing medical education. Nearly all agreed that the government and private institutions should fund training for their workers. In general, those surveyed did not find conflicts of interest in their relationship with the industry (AU)


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Atitude do Pessoal de Saúde , Educação Médica Continuada , Indústria Farmacêutica , Conflito de Interesses , Inquéritos e Questionários , Estudos Transversais
15.
Drug Ther Bull ; 60(9): 135, 2022 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-36002155

RESUMO

Overview of: Ozieranski P, Martinon L, Jachiet PA, et al Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. BMJ Open 2021;11:e053138.


Assuntos
Conflito de Interesses , Revelação , Indústria Farmacêutica , Pessoal de Saúde , Humanos
16.
Alcohol Clin Exp Res ; 46(7): 1153, 2022 07.
Artigo em Inglês | MEDLINE | ID: mdl-35929342
17.
J Am Acad Orthop Surg ; 30(22): 1083-1089, 2022 Nov 15.
Artigo em Inglês | MEDLINE | ID: mdl-36001882

RESUMO

INTRODUCTION: Industry funding in medicine enhances physician training but can create bias influencing accurate reporting of outcomes. High rates of conflict of interest (COI) disclosure have been found in orthopaedic surgery. However, industry-specific disclosures have not been investigated and small-value compensations previously excluded. Using the nerve allograft industry as a proxy to examine specific patterns of COI between physicians and industries relevant to their publications, we sought to evaluate patterns in industry-specific COI disclosure within the hand and upper extremity surgery literature. METHODS: Literature search for primary studies using nerve allografts in the hand and upper extremity from 2013 to 2021 was conducted. Authors were cross-referenced with their publication's COI statement and payments recorded in the Open Payments Database (OPD). Only payments relevant to the topic or product presented in the publication were included. Payments in all OPD subdivisions were compared. RESULTS: Fourteen studies with 14 first, 72 middle, and 14 senior authors were included. Disclosed and undisclosed payments totaled $2,848,196 and $2,509,397. Only 28% of the authors had completely accurate COI statements. Research and food and beverage comprised the highest and lowest average rates of accurate disclosure (93.8% and 24.9%). The value of accurately disclosed payments was significantly greater on a per-author basis among senior authors ( P < 0.001). Neither the value of undisclosed payments nor the rate of accurate disclosure differed by authorship position ( P = 0.904 and P = 0.350). DISCUSSION: When examined in the context of industries specific to publication, the rate of correct COI disclosure is lower than previously reported with small-value compensation a major contributor. Areas of improvement include the following: (1) All authors should be held accountable for correct disclosure; (2) all forms of financial support should be reported; and (3) journals should independently verify disclosures to the OPD. OPD utilization may help verify correct reporting, especially when the industry is related to the area of study, in the interest of maintaining the highest editorial integrity.


Assuntos
Conflito de Interesses , Revelação , Humanos , Autoria , Extremidade Superior , Aloenxertos
20.
BMJ Open ; 12(8): e054325, 2022 08 29.
Artigo em Inglês | MEDLINE | ID: mdl-36038178

RESUMO

OBJECTIVE: To quantify conflicts of interest, assess the accuracy of authors self-reporting them, and examine the association between conflicts of interest and favourability of results and discussions in addiction medicine systematic reviews. DESIGN: A search was performed on Medline (Ovid) from January 2016 to 25 April 2020 to locate systematic reviews and meta-analyses focused on treatments of addiction disorders using a systematic search strategy. Data were extracted from each systematic review, including conflict of interest statements, authorship characteristics and the favourability of the results/conclusion sections. A search algorithm was used to identify any undisclosed conflicts of interest on the Open Payments Database (Dollars for Docs), Dollars for Profs, Google Patents/United States Patent and Trade Office, and prior conflict of interest statements in other published works from these authors. RESULTS: The search identified 127 systematic reviews, representing 665 unique authors. Of the 127 studies, 81 reported no authors with conflicts of interest, 28 with 1 or more conflict, and 18 had no conflict of interest statement. Additional non-disclosed conflicts of interest were found for 34 authors. There were 69 reviews that had at least one author with a conflict of interest. Of the 69 reviews, 14 (20.3%) reported favourable results and 26 (37.7%) reported favourable discussion/conclusions with no statistically significant association. A subanalysis was performed on publications with only US authors (51) with 35 (68.9%) having at least 1 conflict of interest. US authored studies that had a conflict of interest favoured the results (p = <0.001) and discussion/conclusion (p = 0.018) more often. CONCLUSION: Although multiple undisclosed financial conflicts of interest were found, there was no correlation with the favourability of the results or discussion/conclusions across all addiction medicine systematic reviews. Further research needs to be done on US-based publications and encourage disclosure systems worldwide to provide more accurate reporting.


Assuntos
Medicina do Vício , Autoria , Conflito de Interesses , Bases de Dados Factuais , Revelação , Humanos , Metanálise como Assunto , Revisões Sistemáticas como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...